The changing role of technology suppliers in the pharmaceutical industry: The case of drug delivery companies

International Journal of Technology Management

Volumn 25, Issue 3-4, 2003, Pages 350-362

  De Leeuw, Bas J ^a   De Wolf, Peter ^b   Van den Bosch, Frans A J ^b  

^a Focus Inhalation   (Finland)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Appropriability; Pharmaceutical industry; Product development; Technology collaboration

Indexed keywords

BIOTECHNOLOGY; PRODUCT DEVELOPMENT; RESEARCH AND DEVELOPMENT MANAGEMENT; STRATEGIC PLANNING;

TECHNOLOGY COLLABORATION;

DRUG PRODUCTS PLANTS;

EID: 0037282405     PISSN: 02675730     EISSN: None     Source Type: Journal    
DOI: 10.1504/IJTM.2003.003105     Document Type: Article

References (28)

1. Halliday, R.G., Luscombe, D.K. and Walker, S.R. (1995) 'A new look at the world-wide pharmaceutical industry', Journal of Pharmaceutical Medicine, Vol. 5, pp.33-52.
2. Halliday, R.G., Drado, A.L., Lumley, C.E. and Walker, S.R. (1997) 'The allocation of resources for R&D in the world's leading pharmaceutical companies', R&D Management, Vol. 27, No. 1, pp.63-77.
3. diMasi, J., Hansen, R., Grabowski, H. and Lasagna, L. (1991) 'The cost of innovation in the pharmaceutical industry', Journal of Health Economics, Vol. 10, pp. 107-142.
4. diMasi, J.A. (1995) 'New drug development: cost, risk, and complexity', Drug Information Journal.
5. della Valle, F. and Gambardella, A. (1993) 'Biological revolution and strategies for innovation in pharmaceutical companies', R&D Management, Vol. 23, No. 23, pp.287-302.
6. Karrer-Rueedi, E. (1997) 'Adaptation to change: vertical and horizontal integration and development', European Management Journal, Vol. 26, No. 2, pp.461-469.
7. De Wolf, P. (1996) 'External strategic behaviour of the pharmaceutical industry in the European Community', Report of Focus Group OOG, Erasmus University Rotterdam.
8. Ferres, H. (1996) Strategic use of DDS for the 21st Century, Strategic use of DDS, London, IBC Conferences Ltd.
9. Naturally occurring in the human body.
10. Part of peptide or protein or resembles its structure.
11. Powers-Cramer, M. and Saks, S.R. (1994) 'Translating safety, efficacy and compliance into economic value for controlled release dosage forms', PharmacoEconomics Vol. 5, pp.482-502.
12. Plasters containing medical preparations that are absorbed in the bloodstream through the skin.
13. Edwards, M. (1996) 'Drug delivery comes of age', US, Recombinant Capital.
14. Bettis, R.A., Bradley, S.P. and Hamel, G. (1992) 'Outsourcing and industrial decline', Academy of Management Executive, Vol. 6, No. 1, pp.7-22.
15. Lei, D. and Hitt, M.A. (1995) 'Strategic restructuring and outsourcing: The effect of mergers and acquisitions and LBOs on building firm skills and capabilities', Journal of Management, Vol. 21, No. 5, pp.835-859.
16. Pisano, G.P. (1991) 'The governance of innovation: vertical integration and collaborative agreements in the biotechnology industry', Research Policy, Vol. 20, No.2, pp.237-249.
17. Whittaker, E. and Bower, J.D. (1994) 'A shift to external alliances for product development in the pharmaceutical industry', R&D Management, Vol. 24, No. 3, pp.249-260.
18. Spigt, M.H. (1998) 'Strategic renewal in pharmaceutical R&D', Paper presented at EIASM Workshop 'Pharmaceutical and Biotechnology Innovation in the Context of Health Care Reforms', Brussels.
19. Teece, D.J. (1986) 'Profiting from technological innovation', Research Policy, Vol. 15, No. 6, pp.285-305.
20. Mitchell, W. (1989) 'Whether and when? Probability and timing of incumbent's entry into emerging industrial subfields', Administrative Science Quarterly, Vol. 34, pp.208-234.
21. Mitchell, W. (1992) 'Are more good things better: or will technical and market capabilities conflict when a firm expands?', Industrial and Corporate Change, Vol. 1, No. 2, pp.327-346.
22. Tripsas, M. (1997) 'Unraveling the process of creative destruction: complementary assets and incumbent survival in the typesetter industry', Strategic Management Journal, Vol. 18, Summer Special Issue, pp.119-142.
23. van den Bosch, F.A.J. and Elfferich, P.C. (1993) 'Make, buy or cooperate decisions with repsect to research and development in international business networks', in D.D. Sharma (Eds.) Industrial Networks,:JAI Press, Vol. 5, pp. 191-201.
24. von Hippel, E. (1982) The Sources of Innovation, Oxford: Oxford University Press.
25. Sharp, M. (1985) 'Conclusion: technology gap or management gap?', in Europe and the New Technologies; Six Cases in Innovation and Adjustment, M. Sharp (Eds.) London: Frances Pinter.
26. Teece, D.J. (1987) 'Profiting from technological innovation: implications for integration, collaboration, licensing and public policy', in The Theoretical Context of Strategic Management, N. Rosenberg (Eds.) Cambridge, MA: Ballinger Publishing Company pp.185-219.
27. Biotech drugs could also be included in the classes of generic drugs (for example insulin), patented drug (Epogen etc.) or drugs in development, but are regarded as a special class of drugs in this project because of their elevated need for DDS.
28. Pramik, M.J. (1995) 'Drug delivery: strategies to enhance therapeutic value and product positioning', Commercial Report, Decision Resources Inc.